In antitrust litigation concerning HIV drugs, differing plaintiffs’ counsel find themselves in discord. The root of the dispute revolves around allegations that Gilead Sciences Inc. and Teva Pharmaceutical Industries Ltd. entered into a collusive agreement to delay the release of generic versions of HIV drugs. While consumers who lost their cases at trial are eyeing the negotiation for settlement monties, the settling retailers assert that these consumers have no valid claim to the settlement funds.
Reports earlier this week indicated that representatives from both the pharmaceutical giants and retail industry, including CVS, confirmed that the consumer group has no legitimate claim to any part of the settlement. The consumer group had previously lost their battle in court, leaving them technically ineligible for any part of the settlement.
Antitrust allegations in the pharmaceutical sector are not uncommon, often revolving around perceived collusive agreements that directly impact the availability and pricing of major medication classes. This ongoing case, which concerns the potential delay of generic HIV medications, carries enormous implications for consumers and the pharmaceutical industry alike. Should the retailers’ claim hold, it marks yet another noteworthy chapter in the evolving book of antitrust litigation within the healthcare sector.
Further information about the ongoing dispute can be found in the in-depth coverage provided by Law360.